CTOs on the Move

Ceribell

www.ceribell.com

 
Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ceribell.com
  • 360 North Pastoria Avenue
    Sunnyvale, CA USA 94085
  • Phone: 800.436.0826

Executives

Name Title Contact Details
Therese Charles
 Vice President Information Security & IT Profile

Funding

Ceribell raised $35M on 09/25/2018
Ceribell raised $20M on 05/01/2020
Ceribell raised $53M on 04/29/2021

Similar Companies

Cloudbreak

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.

Kirkegaard and Perry Laboratories

KPL is committed to protecting the privacy of our customers. Our Privacy Policy covers any personal information that KPL.com obtains from you when you use services on our site. We use this information to enhance our services and to make them more

VGA Billing Services

VGA Billing Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agenus

Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.

GenomeDx Biosciences

Delivering Genomic Tests that Impact Treatment Decisions GenomeDx develops and commercializes genomic tests for prostate and other urologic cancers that have a direct impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs.